Aurora Investment Counsel Acquires 146 Shares of Lantheus Holdings, Inc. (NASDAQ:LNTH)

Aurora Investment Counsel grew its stake in shares of Lantheus Holdings, Inc. (NASDAQ:LNTH) by 0.8% in the fourth quarter, according to its most recent filing with the SEC. The institutional investor owned 19,200 shares of the medical equipment provider’s stock after purchasing an additional 146 shares during the period. Aurora Investment Counsel’s holdings in Lantheus were worth $1,718,000 as of its most recent filing with the SEC.

Several other institutional investors and hedge funds have also recently modified their holdings of LNTH. Wilmington Savings Fund Society FSB bought a new stake in Lantheus during the third quarter worth $25,000. Kestra Investment Management LLC bought a new stake in shares of Lantheus in the 4th quarter worth $27,000. UMB Bank n.a. raised its holdings in shares of Lantheus by 31.5% in the fourth quarter. UMB Bank n.a. now owns 559 shares of the medical equipment provider’s stock valued at $50,000 after purchasing an additional 134 shares during the last quarter. World Investment Advisors LLC bought a new position in shares of Lantheus during the third quarter valued at about $60,000. Finally, RiverPark Advisors LLC purchased a new position in Lantheus during the third quarter worth about $74,000. 99.06% of the stock is owned by hedge funds and other institutional investors.

Lantheus Price Performance

Shares of NASDAQ LNTH opened at $99.29 on Friday. The stock has a market capitalization of $6.80 billion, a PE ratio of 16.52 and a beta of 0.38. Lantheus Holdings, Inc. has a one year low of $56.44 and a one year high of $126.89. The business’s fifty day moving average price is $91.66 and its 200-day moving average price is $96.89.

Lantheus (NASDAQ:LNTH) last released its quarterly earnings data on Thursday, February 27th. The medical equipment provider reported $1.34 EPS for the quarter, missing the consensus estimate of $1.57 by ($0.23). The business had revenue of $391.11 million for the quarter, compared to analysts’ expectations of $376.61 million. Lantheus had a net margin of 28.57% and a return on equity of 44.29%. As a group, equities analysts expect that Lantheus Holdings, Inc. will post 6.01 EPS for the current fiscal year.

Insider Buying and Selling

In related news, Director James H. Thrall sold 1,000 shares of the stock in a transaction dated Wednesday, January 15th. The stock was sold at an average price of $94.76, for a total transaction of $94,760.00. Following the sale, the director now owns 33,207 shares of the company’s stock, valued at approximately $3,146,695.32. This represents a 2.92 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, Director Mary Anne Heino sold 53,107 shares of Lantheus stock in a transaction dated Monday, March 3rd. The shares were sold at an average price of $94.35, for a total value of $5,010,645.45. Following the transaction, the director now directly owns 440,399 shares of the company’s stock, valued at $41,551,645.65. The trade was a 10.76 % decrease in their position. The disclosure for this sale can be found here. 1.50% of the stock is owned by insiders.

Analysts Set New Price Targets

LNTH has been the subject of several analyst reports. StockNews.com lowered shares of Lantheus from a “buy” rating to a “hold” rating in a research note on Thursday, November 21st. Truist Financial increased their price target on Lantheus from $120.00 to $127.00 and gave the company a “buy” rating in a research report on Thursday, February 27th. The Goldman Sachs Group began coverage on Lantheus in a research report on Wednesday, December 18th. They issued a “buy” rating and a $143.00 price objective on the stock. Finally, JMP Securities reaffirmed a “market outperform” rating and set a $112.00 target price on shares of Lantheus in a research report on Tuesday, January 14th. One analyst has rated the stock with a hold rating and seven have assigned a buy rating to the company’s stock. According to data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and a consensus target price of $132.86.

About Lantheus

Lantheus Holdings, Inc develops, manufactures, and commercializes diagnostic and therapeutic products that assist clinicians in the diagnosis and treatment of heart, cancer, and other diseases worldwide. It provides DEFINITY, an injectable ultrasound enhancing agent used in echocardiography exams; TechneLite, a technetium generator for nuclear medicine procedures; Xenon-133, a radiopharmaceutical gas to assess pulmonary function; Neurolite, an injectable imaging agent to identify the area within the brain where blood flow has been blocked or reduced due to stroke; Cardiolite, an injectable Tc-99m-labeled imaging agent to assess blood flow to the muscle of the heart; and PYLARIFY, an F 18-labelled PSMA-targeted PET imaging agent used for imaging of PSMA positive-lesions in men with prostate cancer.